New challenges in the combination of radiotherapy and immunotherapy in non-small cell lung cancer

doi:10.5306/wjco.v12.i11.983

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 11

This Article

Academic Content and Language Evaluation of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4620)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-5) series.

Item

Count

PDF

249

WORD

102

HTML

2466

Figures (1-1)

171

Tables (1-5)

331

Sum=3319

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

295

Download

337

Sum=632

Publishing Process of This Article

Item

Count

Browse

315

Download

354

Sum=669

Nov 24, 2021 (publication date) through Jul 27, 2024

Times Cited of This Article

Times Cited (3)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Clin Oncol. Nov 24, 2021; 12(11): 983-999
Published online Nov 24, 2021. doi: 10.5306/wjco.v12.i11.983

Table 5 Ongoing clinical trials involving radiotherapy and immunotherapy in stage IV non-small cell lung cancer

Ref.	Phase	ICI agent	RT dose	Design	Primary endpoints
NCT03158883[93]	I	Avelumab	50 Gy/5 fx	ICI + SABR	ORR
NCT03224871[94]	I	Nivolumab; Pembrolizumab; Intratumor IL-2	8 Gy/3 fx	ICI + IL-2 + RT	MTD
NCT03436056, PRIMING[95]	I	Pembrolizumab	SABR 30 Gy-3 fx SABR 54 Gy/3 fx	ICI + SABR	MTD
NCT03812549[96]	I	Sintilimab	SABR 30 Gy/3 fx; LD (low dose)-RT: 2 Gy/1 fx or 4 Gy/2 fx or 10 Gy/5 fx	ICI + SABR; ICI + LD-RT	MTD
NCT03223155, COSINR[69]	I	Nivolumab; Ipilimumab	SABR 3-5 fx, 2-4 sites	ICI + SABR	MTD
NCT02639026[97]	I	Durvalumab; Tremelimumab	HFRT 24 Gy/3 fx, 17 Gy/1 fx	ICI + HFRT	MTD
NCT03275597[98]	I	Durvalumab; Tremelimumab	SABR 30-50 Gy/5 fx	ICI + SABR	MTD
NCT03168464[99]	I-II	Nivolumab; Ipilimumab	RT 30 Gy/5 fx	ICI + RT	ORR
NCT02239900[100]	I-IIR	Ipilimumab	SABR 50 Gy/4 fx or 60 Gy/10 fx; 1-4 lesions	ICI + SABR	MTD
NCT02444741[101]	I-IIR	Pembrolizumab	SABR 4 fx or IMRT, PBRT, 3D-CRT 15 fx	ICI + SABR or IMRT, PBRT, 3D-CRT	MTD, ORR
NCT03176173, RRADICAL[102]	II	Nivolumab; Pembrolizumab; Atezolizumab	SABR 1-10 fx	ICI +/- SABR	PFS
NCT03965468, CHESS[103]	II	Durvalumab	SABR 1-10 fx	ICI + SABR + CT	PFS
NCT03044626, FORCE[104]	II	Nivolumab	RT 20 Gy/5 fx	ICI + RT	ORR
NCT02221739[105]	II	Ipilimumab	IMRT or 3D-CRT 30 Gy/5 fx	ICI + RT	ORR
NCT02658097[106]	II	Pembrolizumab	RT 8 Gy/1 fx	ICI + RT	ORR
NCT03391869, LONESTAR[107]	III	Nivolumab; Ipilimumab	LCT	ICI +/- SABR	OS
NCT03867175[108]	III	Pembrolizumab	SABR 3-10 fx	ICI +/- SABR	PFS
NCT03774732, NIRVANA-LUNG[109]	III	Pembrolizumab	SABR or 3D-CRT 18 Gy/3 fx	ICI + RT + CT	OS

ICI: Immune checkpoint inhibitors; Fx: Fraction; SABR: Stereotactic ablative radiotherapy; RT: Radiotherapy; LD-RT: Low dose radiotherapy; HFRT: Hypofractionated radiotherapy; IMRT: Intensity modulated radiotherapy; PBRT: Proton beam radiation therapy; 3D-CRT: 3D conformal radiation therapy; LCT: Local consolidation therapy; CT: Chemotherapy; ORR: Overall response rate; MTD: Maximum tolerated dose.

Citation: Luna J, Zafra J, Areses Manrique MC, Rodríguez A, Sotoca A, Fírvida JL, Chicas-Sett R, Mielgo X, Reyes JCT, Couñago F. New challenges in the combination of radiotherapy and immunotherapy in non-small cell lung cancer. World J Clin Oncol 2021; 12(11): 983-999
URL: https://www.wjgnet.com/2218-4333/full/v12/i11/983.htm
DOI: https://dx.doi.org/10.5306/wjco.v12.i11.983